<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02206464</url>
  </required_header>
  <id_info>
    <org_study_id>140160</org_study_id>
    <secondary_id>14-I-0160</secondary_id>
    <nct_id>NCT02206464</nct_id>
  </id_info>
  <brief_title>H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...</brief_title>
  <official_title>VRC 315: A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boost</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&lt;TAB&gt;&#xD;
&#xD;
      - Flu virus that causes disease in birds can sometimes spread to people. It can cause severe&#xD;
      illness, even death. Vaccines are used to try to create resistance to such infections.&#xD;
      Researchers want to test a new vaccination strategy, combining two different vaccine types,&#xD;
      the H7 DNA Vaccine (DNA vaccine) and H7N9 Monovalent Inactivated Vaccine (MIV), to see if one&#xD;
      of two combinations offer better protection against a certain type of bird flu in humans when&#xD;
      compared to vaccination using two doses of MIV alone.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To see if 2 vaccines for bird flu, are safe and tolerable for humans.&#xD;
&#xD;
        -  To study immune responses to these vaccines.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Healthy adults 18 60 years old.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened through a separate protocol.&#xD;
&#xD;
        -  Participants will be randomly assigned to 1 of 3 groups. Each group will get a different&#xD;
           combination of vaccines.&#xD;
&#xD;
        -  Participants will have about 8 clinic visits. Each visit takes 2 4 hours. Blood will be&#xD;
           drawn at some visits. Urine samples may be collected.&#xD;
&#xD;
        -  Participants will receive vaccinations at 2 of the visits, 16 weeks apart.&#xD;
&#xD;
        -  The H7N9 MIV will be injected in the upper arm using a needle and syringe. The DNA&#xD;
           vaccine will be injected in the upper arm using a device that delivers the vaccine&#xD;
           through the skin by pressure instead of a needle.&#xD;
&#xD;
        -  Participants will be observed for at least 30 minutes after each vaccination.&#xD;
&#xD;
        -  Soon after each vaccination, participants will get 1 2 phone calls, come to clinic for&#xD;
           evaluation, and complete a diary at home for 1 week. They will record their temperature&#xD;
           and symptoms and look at the injection site daily.&#xD;
&#xD;
        -  Participants will have follow-up blood tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VRC 315 STUDY:&#xD;
&#xD;
      A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy&#xD;
      Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or with&#xD;
      Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime with MIV Boost Compared to&#xD;
      MIV Prime with MIV Boost&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and&#xD;
      immunogenicity of prime-boost vaccination regimens against H7N9 Influenza. A vaccination&#xD;
      regimen with the VRC-FLUDNA071-00-VP (H7 DNA) vaccine administered alone or concurrently in&#xD;
      different arms with A/Shanghai/2/2013(H7N9) (MIV) as prime followed by inactivated MIV boost&#xD;
      will be compared to MIV-MIV prime-boost with a 16 week boost interval. The primary hypothesis&#xD;
      is that all the H7 DNA prime-MIV boost, DNA+MIV prime-MIV boost, and MIV-MIV study regimens&#xD;
      will be safe for human administration. A secondary hypothesis is that the H7 DNAMIV regimen&#xD;
      will elicit a greater frequency and/or magnitude of antibody against H7 than the MIV-MIV&#xD;
      regimen. The primary objective is to evaluate the safety and tolerability in healthy adults&#xD;
      of the investigational vaccine regimens. Secondary objectives are related to the&#xD;
      immunogenicity of the vaccination regimens.&#xD;
&#xD;
      PRODUCT DESCRIPTION:&#xD;
&#xD;
      The investigational VRC-FLUDNA071-00-VP vaccine was developed by VRC, NIAID and is composed&#xD;
      of a single closed-circular DNA plasmid that encodes the H7 hemagglutinin (HA) protein of&#xD;
      A/Anhui/1/2013 (H7N9) influenza, and is supplied in single dose vials at a concentration of 4&#xD;
      mg/mL. H7 DNA vaccinations will be 4 mg administered as a 1 mL intramuscularly (IM) using the&#xD;
      Biojector o 2000 Needle-Free Injection Management System (Biojector). The inactivated H7N9&#xD;
      vaccine is monovalent subunit virion vaccine, A/Shanghai/2/2013(H7N9) MIV, manufactured by&#xD;
      Sanofi Pasteur, Inc (Swiftwater, PA), and supplied at 30 mcg/0.5 mL per vial. The H7N9 MIV&#xD;
      vaccinations will be 45 mcg administered as a 0.75 mL IM injection using needle and syringe.&#xD;
      All injections will be in the deltoid muscle.&#xD;
&#xD;
      SUBJECTS:&#xD;
&#xD;
      A total of up to 36 healthy adults, ages 18-60 years will be enrolled.&#xD;
&#xD;
      STUDY PLAN:&#xD;
&#xD;
      Subjects will be randomized equally into the three study groups and will receive two&#xD;
      vaccinations as shown in the schema. The protocol requires 7 clinic visits and a telephone&#xD;
      follow-up contact after each study injection. Durability of immune response will be followed&#xD;
      through Study Week 28.&#xD;
&#xD;
      STUDY DURATION:&#xD;
&#xD;
      Subjects will be evaluated for safety and immune responses throughout the study for 12 weeks&#xD;
      following the boost. Duration of time on study will be 28 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 29, 2014</start_date>
  <completion_date type="Actual">January 7, 2016</completion_date>
  <primary_completion_date type="Actual">January 7, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited adverse events (reactogenicity).</measure>
    <time_frame>Daily for 7 days following each vaccination.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of all severities.</measure>
    <time_frame>Through 28 days after each injection.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events, new chronic medical conditions and influenza-like illnesses</measure>
    <time_frame>From first vaccination to last study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>H7-specific antibody response as measured by HAI assay</measure>
    <time_frame>Day 0 (baseline) and 2 weeks after the boost vaccination.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/Shanghai/02/2013 (H7N9) MIV</intervention_name>
    <description>Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-FLUDNA071-00-VP</intervention_name>
    <description>H7 DNA Vaccine</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        A subject must meet all of the following criteria:&#xD;
&#xD;
          1. 18 to 60 years old.&#xD;
&#xD;
          2. Available for clinic visits for up to 28 weeks after enrollment.&#xD;
&#xD;
          3. Able to provide proof of identity to the satisfaction of the study clinician&#xD;
             completing the enrollment process.&#xD;
&#xD;
          4. Willing to donate blood for sample storage to be used for future research.&#xD;
&#xD;
          5. In good general health without clinically significant medical history.&#xD;
&#xD;
          6. Received a current seasonal influenza vaccine at least 2 weeks before enrollment.&#xD;
&#xD;
          7. Physical examination and laboratory results without clinically significant findings&#xD;
             and a Body Mass Index (BMI) less than or equal to 40 within the 56 days prior to&#xD;
             enrollment.&#xD;
&#xD;
             Laboratory Criteria within 56 days prior to enrollment:&#xD;
&#xD;
          8. Hemoglobin within institutional normal limits&#xD;
&#xD;
          9. White blood cells (WBC) and differential either within institutional normal range or&#xD;
             accompanied by site physician approval&#xD;
&#xD;
         10. Total lymphocyte count greater than or equal to 800 cells/mm3&#xD;
&#xD;
         11. Platelets = 125,000 500,000/mm3&#xD;
&#xD;
         12. Alanine aminotransferase (ALT) less than or equal to 1.25 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
         13. Serum creatinine less than or equal to .1 x ULN based on the institutional normal&#xD;
             range&#xD;
&#xD;
             Criteria applicable to women of childbearing potential:&#xD;
&#xD;
         14. Negative human chorionic gonadotropin ( &lt;=-HCG) pregnancy test (urine or serum) on day&#xD;
             of enrollment&#xD;
&#xD;
         15. Agree to use an effective means of birth control from 21 days prior to enrollment&#xD;
             through 4 weeks after the second study vaccination&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        A subject will be excluded if one or more of the following conditions apply. Women&#xD;
        Specific:&#xD;
&#xD;
          1. Breast-feeding or planning to become pregnant while participating in the study&#xD;
&#xD;
             Subject has received any of the following substances:&#xD;
&#xD;
          2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications&#xD;
             within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment&#xD;
&#xD;
          3. Blood products within 16 weeks prior to enrollment&#xD;
&#xD;
          4. Live attenuated vaccines within 4 weeks prior to initial study vaccine administration&#xD;
&#xD;
          5. Investigational research agents within 4 weeks prior to enrollment or planning to&#xD;
             receive investigational products while on the study&#xD;
&#xD;
          6. Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal within 2&#xD;
             weeks of initial study vaccine administration unless approved by the study Principal&#xD;
             Investigator (PI)&#xD;
&#xD;
          7. Allergy treatment with antigen injections, unless on maintenance schedule&#xD;
&#xD;
          8. Current anti-TB prophylaxis or therapy&#xD;
&#xD;
          9. Previous H7 avian influenza investigational vaccine&#xD;
&#xD;
             Subject has a history of any of the following clinically significant conditions:&#xD;
&#xD;
         10. Contraindication to receiving an FDA-approved current seasonal influenza vaccination&#xD;
             including hypersensitivity to eggs&#xD;
&#xD;
         11. Serious reactions to vaccines that preclude receipt of study vaccinations as&#xD;
             determined by the investigator&#xD;
&#xD;
         12. Hereditary angioedema, acquired angioedema, or idiopathic forms of Angioedema&#xD;
&#xD;
         13. Asthma that is unstable or required emergent care, urgent care, hospitalization or&#xD;
             intubation during the past two years or that requires the use of oral or intravenous&#xD;
             corticosteroids&#xD;
&#xD;
         14. Diabetes mellitus (type I or II), with the exception of gestational diabetes&#xD;
&#xD;
         15. Thyroid disease that is not well controlled&#xD;
&#xD;
         16. Idiopathic urticaria within the past year&#xD;
&#xD;
         17. Hypertension that is not well controlled&#xD;
&#xD;
         18. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws&#xD;
&#xD;
         19. Malignancy that is active or treated malignancy for which there is not reasonable&#xD;
             assurance of sustained cure or malignancy that is likely to recur during the period of&#xD;
             the study&#xD;
&#xD;
         20. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol&#xD;
             withdrawal more than 3 years ago, or 3) seizures that have not required treatment&#xD;
             within the last 3 years&#xD;
&#xD;
         21. Asplenia, functional asplenia or any condition resulting in the absence or removal of&#xD;
             the spleen.&#xD;
&#xD;
         22. Type 1 hypersensitivity reaction to aminoglycoside antibiotics&#xD;
&#xD;
         23. Guillain-Barr(SqrRoot)(Copyright) Syndrome&#xD;
&#xD;
         24. Psychiatric condition that precludes compliance with the protocol; past or present&#xD;
             psychoses; past or present bipolar disorder; disorder requiring lithium; or within 5&#xD;
             years prior to enrollment, a history of suicide plan or attempt&#xD;
&#xD;
         25. Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer s ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie E Ledgerwood, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ledgerwood JE, Graham BS. DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin. 2009 Sep;5(9):623-6. doi: 10.4161/hv.8627. No abstract available.</citation>
    <PMID>19779298</PMID>
  </reference>
  <reference>
    <citation>Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011 Dec;11(12):916-24. doi: 10.1016/S1473-3099(11)70240-7. Epub 2011 Oct 3.</citation>
    <PMID>21975270</PMID>
  </reference>
  <reference>
    <citation>Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 310 Study Team. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013 Aug 1;208(3):418-22. doi: 10.1093/infdis/jit180. Epub 2013 Apr 30.</citation>
    <PMID>23633407</PMID>
  </reference>
  <verification_date>January 7, 2016</verification_date>
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>July 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>December 14, 2019</last_update_submitted>
  <last_update_submitted_qc>December 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>A/Anhui/1/2013 (H7N9)</keyword>
  <keyword>Antibody Response</keyword>
  <keyword>Avian Influenza</keyword>
  <keyword>A/Shanghai/2/2013 (H7N9)</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02206464
org study id: 140160
secondary id: 14-I-0160
nct id: NCT02206464
lead sponsor: 
Background:<TAB>

      - Flu virus that causes disease in birds can sometimes spread to people. It can cause severe
      illness, even death. Vaccines are used to try to create resistance to such infections.
      Researchers want to test a new vaccination strategy, combining two different vaccine types,
      the H7 DNA Vaccine (DNA vaccine) and H7N9 Monovalent Inactivated Vaccine (MIV), to see if one
      of two combinations offer better protection against a certain type of bird flu in humans when
      compared to vaccination using two doses of MIV alone.

      Objectives:

        -  To see if 2 vaccines for bird flu, are safe and tolerable for humans.

        -  To study immune responses to these vaccines.

      Eligibility:

      - Healthy adults 18 60 years old.

      Design:

        -  Participants will be screened through a separate protocol.

        -  Participants will be randomly assigned to 1 of 3 groups. Each group will get a different
           combination of vaccines.

        -  Participants will have about 8 clinic visits. Each visit takes 2 4 hours. Blood will be
           drawn at some visits. Urine samples may be collected.

        -  Participants will receive vaccinations at 2 of the visits, 16 weeks apart.

        -  The H7N9 MIV will be injected in the upper arm using a needle and syringe. The DNA
           vaccine will be injected in the upper arm using a device that delivers the vaccine
           through the skin by pressure instead of a needle.

        -  Participants will be observed for at least 30 minutes after each vaccination.

        -  Soon after each vaccination, participants will get 1 2 phone calls, come to clinic for
           evaluation, and complete a diary at home for 1 week. They will record their temperature
           and symptoms and look at the injection site daily.

        -  Participants will have follow-up blood tests.
VRC 315 STUDY:

      A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy
      Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or with
      Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime with MIV Boost Compared to
      MIV Prime with MIV Boost

      STUDY DESIGN:

      This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and
      immunogenicity of prime-boost vaccination regimens against H7N9 Influenza. A vaccination
      regimen with the VRC-FLUDNA071-00-VP (H7 DNA) vaccine administered alone or concurrently in
      different arms with A/Shanghai/2/2013(H7N9) (MIV) as prime followed by inactivated MIV boost
      will be compared to MIV-MIV prime-boost with a 16 week boost interval. The primary hypothesis
      is that all the H7 DNA prime-MIV boost, DNA+MIV prime-MIV boost, and MIV-MIV study regimens
      will be safe for human administration. A secondary hypothesis is that the H7 DNAMIV regimen
      will elicit a greater frequency and/or magnitude of antibody against H7 than the MIV-MIV
      regimen. The primary objective is to evaluate the safety and tolerability in healthy adults
      of the investigational vaccine regimens. Secondary objectives are related to the
      immunogenicity of the vaccination regimens.

      PRODUCT DESCRIPTION:

      The investigational VRC-FLUDNA071-00-VP vaccine was developed by VRC, NIAID and is composed
      of a single closed-circular DNA plasmid that encodes the H7 hemagglutinin (HA) protein of
      A/Anhui/1/2013 (H7N9) influenza, and is supplied in single dose vials at a concentration of 4
      mg/mL. H7 DNA vaccinations will be 4 mg administered as a 1 mL intramuscularly (IM) using the
      Biojector o 2000 Needle-Free Injection Management System (Biojector). The inactivated H7N9
      vaccine is monovalent subunit virion vaccine, A/Shanghai/2/2013(H7N9) MIV, manufactured by
      Sanofi Pasteur, Inc (Swiftwater, PA), and supplied at 30 mcg/0.5 mL per vial. The H7N9 MIV
      vaccinations will be 45 mcg administered as a 0.75 mL IM injection using needle and syringe.
      All injections will be in the deltoid muscle.

      SUBJECTS:

      A total of up to 36 healthy adults, ages 18-60 years will be enrolled.

      STUDY PLAN:

      Subjects will be randomized equally into the three study groups and will receive two
      vaccinations as shown in the schema. The protocol requires 7 clinic visits and a telephone
      follow-up contact after each study injection. Durability of immune response will be followed
      through Study Week 28.

      STUDY DURATION:

      Subjects will be evaluated for safety and immune responses throughout the study for 12 weeks
      following the boost. Duration of time on study will be 28 weeks.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: None (Open Label)
measure: Solicited adverse events (reactogenicity).
time frame: Daily for 7 days following each vaccination.
measure: Adverse events of all severities.
time frame: Through 28 days after each injection.
measure: Serious adverse events, new chronic medical conditions and influenza-like illnesses
time frame: From first vaccination to last study visit
measure: H7-specific antibody response as measured by HAI assay
time frame: Day 0 (baseline) and 2 weeks after the boost vaccination.
arm group label: Group 1
arm group type: Experimental
description: H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
arm group label: Group 2
arm group type: Experimental
description: H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
arm group label: Group 3
arm group type: Experimental
description: H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
intervention type: Biological
intervention name: A/Shanghai/02/2013 (H7N9) MIV
description: Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
intervention type: Biological
intervention name: VRC-FLUDNA071-00-VP
description: H7 DNA Vaccine
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: No
last name: Julie E Ledgerwood, D.O.
role: Principal Investigator
affiliation: National Institute of Allergy and Infectious Diseases (NIAID)
facility: 
country: United States
citation: Ledgerwood JE, Graham BS. DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin. 2009 Sep;5(9):623-6. doi: 10.4161/hv.8627. No abstract available.
PMID: 19779298
citation: Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011 Dec;11(12):916-24. doi: 10.1016/S1473-3099(11)70240-7. Epub 2011 Oct 3.
PMID: 21975270
citation: Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 310 Study Team. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013 Aug 1;208(3):418-22. doi: 10.1093/infdis/jit180. Epub 2013 Apr 30.
PMID: 23633407
responsible party type: Sponsor
mesh term: Influenza, Human
mesh term: Influenza in Birds